BioSpace News Archive

A New Business Strategy report released by Data Bridge Market Research with the title Global Active Pharmaceutical Ingredients (API) Market Study Forecast till 2028.

As part of an enduring commitment to equipping surgeons in the federal healthcare system with the best tools possible, MellingMedical is pleased to provide access to the full suite offered by Fehling Surgical Instruments, Inc.

Eurofins DiscoverX announced the official opening of its new China biotechnology office in Shanghai.

Hoth Therapeutics, Inc. announced that the Company received confirmation from the Listing Qualification Department of The NASDAQ Capital Market notifying the Company that Nasdaq has granted the Company an additional 180-day compliance period, or until December 26, 2022, to regain compliance with Nasdaq’s minimum $1.00 closing bid price per share requirement.

StarAligners, Inc, a leader and innovator of clear aligners, orthodontic products, and solutions, announces the launch of Illumina™, an innovative orthodontic product new to the market.

On Friday, U.S. Senators Chris Van Hollen (D-MD) and Ben Ray Lujan (D-NM), and U.S. Reps. Don Beyer (D-VA), and Kim Schrier (D-WA) introduced legislation, the Improving Diagnosis in Medicine Act of 2022 (H.R.8172/S.4468) to focus federal health agencies on tackling the root causes of diagnostic error.

A New Business Strategy report released by Data Bridge Market Research with the title Global Autoimmune Disease Diagnosis Market Study Forecast till 2029.

A New Research on the Artificial Intelligence (AI) in Drug Discovery Market was conducted across a variety of industries in various regions to produce more than 350+ page reports.

3Spine, Inc., a medical device company developing total joint replacement for the lumbar spine, announced completion of the first series of US surgeries in the BalancedBack Total Joint Replacement Investigational Device Exemption pivotal clinical trial.

Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced an executive leadership transition.